oncolex logo
Utskriftsdato 6.6.2020

Referanser til kreft i analkanal

  1. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av analcancer (2017), Helsedirektoratet
  2. Cancer in Norway 2018, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
  3. Tanum G. Treatment of relapsing anal carcinoma. Acta Oncol 1993; 32(1): 33–35
  4. Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology 111 (2014) 330-339
  5. James RD, Glynne-Jones R, Meadows HM, Maughan T et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. 2013 May;14(6):516-24
  6. Ajani JA, Winter KA, Gunderson LL et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA Apr 23;299(16):1914-21
  7. Guren MG, Dueland S, Skovlund E, Fosså SD, Poulsen JP, Tveit KM. Quality of life during radiotherapy for rectal cancer. Eur J Cancer 2003 Mar; 39(5):587-94.
  8. Bentzen AG, Guren MG, Wanderås EH, Frykholm G, Tveit KM, Wilsgaard T, Dahl O, Balteskard L. Chemotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. Int J Radiat Oncol Biol Phys. 2012 jun 1;83(2):e173-80
  9. Bentzen AG, Balteskard L, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Guren MG. Impaired health related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013 May; 52 (4):736-44
  10. Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Balteskard L. Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiother Oncol. 2013 Jul;108(1):55-60
  11. Nilsson PJ, Svensson C, Goldman S, Glimelius B. Salvage abdominoperineal resection in anal epidermoid cancer. Br J Surg 2002; 89(11): 1425–9
  12. Bai YK, Cao WL, Gao JD, Liang J, Shao YF. Surgical salvage therapy of anal cancer. World J Gastroenterol 2004; 10(3): 424-6
  13. Barbaro G, Barbarini G. HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep 2007; 17(5): 1121-6
  14. Bell SW, Dehni N, Chaouat M, Lifante JC, Parc R, Tiret E. Primary rectus abdominis myocutaneous flap for repair of perineal and vaginal defects after extended abdominoperineal resection. Br J Surg 2005; 92(4): 482–486
  15. Dev VR, Gupta A. Plastic and reconstructive surgery approaches in the management of anal cancer. Surg Oncol Clin N Am 2004; 13(2): 339-53
  16. Tei TM, Stolzenburg T, Buntzen S, Laurberg S, Kjeldsen H. Use of transpelvic rectus abdominis musculocutaneous flap for anal cancer salvage surgery. Br J Surg 2003; 90(5): 575-80